Daiichi, Sankyo Deal Aimed At Fending Off Foreign Competition In Japan
This article was originally published in The Pink Sheet Daily
The new company, Daiichi Sankyo, will be the second largest Japanese pharmaceutical company based on domestic sales. The top 10 Japanese pharma companies have lost 3% of market share in the last 13 years, while the top 10 foreign companies have gained significantly, Daiichi's CEO says.
You may also be interested in...
Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.